Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
Inv. presentation
Director departure
DERMA SCIENCES, INC. (DSCI) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/06/2017 8-K/A Quarterly results
02/24/2017 8-K Form 8-K - Current report
01/25/2017 8-K Form 8-K - Current report
01/17/2017 8-K Form 8-K - Current report
01/17/2017 8-K Form 8-K - Current report
10/21/2016 8-K/A Financial Statements and Exhibits
Docs: "CONSENT OF BDO USA, LLP, INDEPENDENT AUDITORS",
"BioD, LLC and Subsidiaries Consolidated Financial Statements Fiscal Years Ended December 31, 2015 and 2014 BioD, LLC and Subsidiaries Contents Independent Auditor’ s Report 3-4 Consolidated Financial Statements Balance Sheets 6 Statements of Operations and Changes in Members’ Equity 7 Statements of Cash Flows 8 Notes to Consolidated Financial Statements 9-19 2 Tel: 901-680-7600 6075 Poplar Ave, Suite 630 Fax: 901-680-7601 Memphis, TN 38119 www.bdo.com Independent Auditor’ s Report Board of Directors BioD, LLC and Subsidiaries Memphis, Tennessee We have audited the accompanying consolidated financial statements of BioD, LLC and Subsidiaries , which comprise the consolidated balance sheets as of December 31, 2015 and 2014, and the related consolidated statements of operations and changes in ...",
"UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS OF BIOD, LLC AND SUBSIDIARIES FOR THE SIX MONTHS ENDED JUNE 30, 2016 AND 2015 Unaudited Consolidated Balance Sheet 1 Unaudited Consolidated Statements of Operations and Changes in Members’ Equity 2 Unaudited Consolidated Statements of Cash Flows 3 Notes to Unaudited Interim Consolidated Financial Statements 4 BioD, LLC and Subsidiaries Consolidated Balance Sheet June 30, 2016 December 31, 2015 Assets Current Assets Cash and cash equivalents $ 136,633 $ 1,353,496 Accounts receivable, less allowance for doubtful accounts of approximately $520,000 and $520,000, respectively 5,211,869 4,914,802 Current portion of notes receivable 374,667 - Inventories 1,161,000 498,841 Prepaid expenses and other current assets 117,465 95,981 Total Current Ass...",
"DERMA SCIENCES, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS Overview 1 Unaudited Pro Forma Consolidated Balance Sheet as of June 30, 2016 3 Unaudited Pro Forma Consolidated Statement of Operations for the Six Months Ended June 30, 2016 4 Unaudited Pro Forma Consolidated Statement of Operations for the Year Ended December 31, 2015 5 Notes to the Unaudited Pro Forma Consolidated Financial Statements 6 DERMA SCIENCES, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS Overview On August 5, 2016, Derma Sciences, Inc. through a wholly owned subsidiary, acquired all of the membership interests in BioD, LLC pursuant to the terms of the Agreement and Plan of Merger dated July 27, 2016 . BioD is a vertically integrated biotechnology company engaged in the development and comm..."
09/08/2016 8-K Form 8-K - Current report
08/26/2016 8-K Form 8-K - Current report
08/11/2016 8-K Form 8-K - Current report
07/29/2016 8-K Investor presentation
Docs: "Separation Agreement",
"# # #",
"Slide Presentation"
06/03/2016 8-K Form 8-K - Current report
03/01/2016 8-K Resignation/termination of a director
12/21/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement, between Derma Sciences, Inc. and Edward J. Quilty",
"DERMA SCIENCES ANNOUNCES LEADERSHIP AND CEO TRANSITION"
08/07/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/29/2015 8-K Submission of Matters to a Vote of Security Holders
05/23/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "2014 Director Compensation Program",
"Amended and Restated Derma Sciences, Inc. 2012 Equity Incentive Plan"
03/27/2014 8-K Resignation/termination of a director
01/27/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Purchase Agreement, by and between the Company and Piper Jaffray & Co. and Canaccord Genuity Inc., as Representatives of the several Underwriters",
"Purchase Agreement, by and between the Company and Piper Jaffray & Co. and Canaccord Genuity Inc., as Representatives of the several Underwriters",
"Opinion of Thompson Hine LLP",
"Opinion of Thompson Hine LLP",
"DERMA SCIENCES ANNOUNCES COMMENCEMENT OF PUBLIC OFFERING OF COMMON STOCK",
"DERMA SCIENCES ANNOUNCES COMMENCEMENT OF PUBLIC OFFERING OF COMMON STOCK",
"Derma Sciences Announces Pricing of UNDERWRITTEN PUBLIC Offering of Common Stock",
"Derma Sciences Announces Pricing of UNDERWRITTEN PUBLIC Offering of Common Stock"
01/21/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Derma Sciences Announces Record Revenues for the 2013 Fourth Quarter and Full Year, Introduces 2014 Revenue Guidance, Provides Update on DSC127 Phase 3 Clinical Trials Expects 2014 total revenue of $92 million, up 15.5% over 2013, organic advanced wound care revenue growth of 30% to 40%"
01/17/2014 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Derma Sciences Enters the Skin Substitute Market with Licensing Agreement for Innovative Amniotic Membrane Wound Care Products Commercial launch into this $500 million market, along with its drug candidate for the treatment of diabetic foot ulcers, underscores company’ s commitment to regenerative medicine"
09/05/2013 8-K Form 8-K - Current report
08/12/2013 8-K Form 8-K - Current report
05/24/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "2013 Director Compensation Program",
"Amended and Restated Derma Sciences, Inc. 2012 Equity Incentive Plan"
04/01/2013 8-K Resignation/termination of a director
12/21/2012 8-K Form 8-K - Current report
12/10/2012 8-K/A Financial Statements and Exhibits
Docs: "Purchase Agreement, by and between the Company and Piper Jaffray & Co., as Representative of the several Underwriters"
12/07/2012 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Opinion of Thompson Hine LLP",
"DERMA SCIENCES ANNOUNCES COMMENCEMENT OF PUBLIC OFFERING OF COMMON STOCK",
"Derma Sciences Announces Pricing of UNDERWRITTEN PUBLIC Offering of Common Stock"
09/20/2012 8-K Form 8-K - Current report
07/18/2012 8-K Form 8-K - Current report
07/03/2012 8-K Form 8-K - Current report
06/29/2012 8-K/A Financial Statements and Exhibits
Docs: "CONSENT OF GHP HORWATH, P.C., INDEPENDENT AUDITORS",
"INDEPENDENT AUDITORS’ REPORT",
"UNAUDITED INTERIM FINANCIAL STATEMENTS OF MEDEFFICIENCY, INC. FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011",
"DERMA SCIENCES, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS"
06/05/2012 8-K Form 8-K - Current report
05/18/2012 8-K Form 8-K - Current report
05/04/2012 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy